# QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

> **NCT03132155** · PHASE2 · TERMINATED · sponsor: **NantPharma, LLC** · enrollment: 8 (actual)

## Conditions studied

- Clear Cell Sarcoma

## Interventions

- **DRUG:** AMG 337

## Key facts

- **NCT ID:** NCT03132155
- **Lead sponsor:** NantPharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-29
- **Primary completion:** 2021-08-13
- **Final completion:** 2021-09-21
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Prematurely terminated due to lack of therapeutic effect
- **Last updated:** 2024-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03132155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03132155, "QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03132155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*